



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



ML-145

Item No. 33534

CAS Registry No.: 1164500-72-4
Formal Name: 2-hydroxy-4-[[4-[(5Z)-5-[(2E)-2-methyl-3-phenyl-2-propen-1-ylidene]-4-oxo-2-thioxo-3-thiazolidinyl]-1-oxobutyl]amino]-benzoic acid
MF: C₂₄H₂₂N₂O₅S₂
FW: 482.6
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ML-145 is supplied as a solid. A stock solution may be made by dissolving the ML-145 in the solvent of choice, which should be purged with an inert gas. ML-145 is soluble in DMSO (sonicated) at a concentration of 50 mg/ml.

Description

ML-145 is an antagonist of G protein-coupled receptor 35 (GPR35).¹ It inhibits β -arrestin recruitment induced by the GPR35 agonists zaprinast (Item No. 10010421), cromolyn (Item No. 21379), and pamoic acid (Item No. 13946) in HEK293 cells expressing the human receptor (EC_{50} s = 26, 22, and 8.3 nM, respectively). ML-145 inhibits constitutive and agonist-mediated D-myoinositol-1-phosphate (IP₁) accumulation in cells expressing human, but not rat, GPR35 in a concentration-dependent manner.

Reference

1. Jenkins, L., Harries, N., Lappin, J.E., *et al.* Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. *J. Pharmacol. Exp. Ther.* **343(3)**, 683-695 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/10/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM